Disease research

How are the human prion diseases grouped?

The CDC names Creutzfeldt-Jakob disease as the most common human prion disease, with variant CJD a separate and much rarer disease, alongside kuru, variably protease-sensitive prionopathy, sporadic fatal insomnia and the inherited forms. It groups causes as sporadic, where most classic CJD appears with no known reason, inherited, and acquired through contaminated food, organ transplants or contaminated surgical equipment. It names bovine spongiform encephalopathy and chronic wasting disease as the best known animal prion diseases in the United States, and states that there is no treatment or vaccine and that prion diseases are always fatal.

The 2026 Viruses review gives the proportions. Sporadic CJD accounts for about 85 percent of cases, with a stable global incidence of 1 to 2 per million per year. Iatrogenic CJD accounts for under 1 percent of all human prion disease, and the review describes acquired forms as exceedingly rare because of stronger preventive measures. It describes the genetic forms as less common and highly heterogeneous, with more than 20 pathogenic PRNP mutations, and does not assign them a single percentage.

National surveillance figures do not agree precisely on the inherited share. The Canadian factsheet reports about 93 percent sporadic, about 6 percent inherited and under 1 percent acquired, while the Canadian public dashboard states that genetic CJD makes up 5 to 15 percent of diagnosed cases. Both come from the same surveillance system.

What does the molecular classification name?

Molecular subtypes combine the codon 129 genotype, which is methionine homozygous, heterozygous or valine homozygous, with prion protein type 1 or type 2. The Viruses review lists MM1, MM2-cortical, MM2-thalamic, MV1, MV2, VV1 and VV2, names MM1 as the most common subtype, and gives VV2 as about 15 percent of sporadic cases. It also notes that nearly all variant CJD patients are methionine homozygous at codon 129.

The subtype names do more work than description. They predict clinical course, assay sensitivity and strain behaviour in animal models, which is why they appear throughout the diagnostic and strain literature. They are set out in sporadic CJD subtypes.

Where do the genetic phenotypes sit?

The genetic group is usually divided into three phenotypes rather than three diseases. NCBI MedGen returns inherited Creutzfeldt-Jakob disease for OMIM 123400 and describes it as a genetic prion disease with three major phenotypes: genetic CJD, fatal familial insomnia and Gerstmann-Straussler-Scheinker syndrome. The same PRNP variant can produce more than one of these presentations within a family, which is why the phenotype labels and the variant names are both reported in case series.

Each of these has its own literature and its own page: genetic prion disease, fatal familial insomnia and Gerstmann-Straussler-Scheinker.

Which diseases have their own research questions?

The aetiological groups do not share a research agenda.

Sporadic CJD carries most of the diagnostic and therapeutic trial literature, because it supplies most patients. Creutzfeldt-Jakob disease covers the work that spans the CJD forms, including the therapeutic programmes.

Genetic prion disease is where presymptomatic research sits, because carriers can be identified before onset. That makes it the group where prevention trials and reproductive options are discussed, and where genetic counselling practice is studied.

Variant CJD and iatrogenic CJD are driven by exposure questions and surveillance rather than by patient numbers. Kuru is now historical and informs incubation period and genetic resistance work. Variably protease-sensitive prionopathy was separated out recently and remains small enough that its case definition is still being refined.

What is changing across all of them?

The 2026 Lancet Neurology review states that blood-based diagnostic biomarkers are now close to clinical application, that research is moving towards presymptomatic mutation carriers and non-invasive sampling in blood, tear fluid and urine, and that a disease staging system based on biomarkers should be evaluated in future clinical studies. That changes what a disease label is being asked to carry, because staging requires a measurement of position within a course rather than a classification of which disease is present.

The Viruses review states that no approved therapy alters the course of prion disease, that management is symptomatic and palliative, that quinacrine failed in a randomised trial and in the PRION-1 cohort, that the anti-PrP antibody PRN100 showed acceptable safety and central nervous system penetration without proven efficacy, that antisense oligonucleotides and RNA interference are in early-phase trials, and that gene therapy and stem cell approaches remain preclinical.

The assays that separate these diseases are described in diagnostics research, the population figures in epidemiology, and the wider programme map in research.